CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
Key Highlights
- ➤CVRx (CVRX) will release Q3 2026 results after market close November 5, 2026
- ➤Conference call scheduled for 4:30 p.m. Eastern Time on November 5
- ➤Barostim is FDA-approved for U.S. heart failure patients
- ➤Barostim holds CE Mark for heart failure and resistant hypertension in the EEA
MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
Get started
Create a free account to read the full story.